Zydus Lifesciences shares rise after USFDA nod, RK Pharma licensing deal

Zydus Lifesciences gained 2 per cent after securing USFDA approval for Verapamil ER tablets and signing an exclusive deal with RK Pharma

Shares of Zydus Lifesciences Ltd. rose nearly 2 per cent on Wednesday after it received final approval from the United States Food and Drug Administration (USFDA) for Verapamil Hydrochloride Extended-Release Tablets. It also entered into an exclusive licensing and commercialisation agreement with RK Pharma. 

 

The pharma major's stock rose as much as 1.65 per cent during the day to ₹943.7 per share, the biggest intraday rise since November 12 this year. The Zydus Lifesciences stock pared gains to trade 1.5 per cent higher at ₹942.4 apiece, compared to a 1.16 per cent advance in Nifty 50 as of 1:23 PM. 

 

 

Shares of the company rose for the third straight session on Wednesday. The counter has fallen 3 per cent so far this year, compared to a 10.7 per cent advance in the benchmark Nifty 50. Zydus Lifesciences has a total market capitalisation of ₹94,631.28 crore.   FOLLOW LATEST STOCK MARKET UPDATES TODAY LIVE

Zydus Lifesciences gets USFDA approval for Verapamil ER tablets

Zydus Lifesciences has received final approval from the US Food and Drug Administration (USFDA) for its Verapamil Hydrochloride extended-release tablets in 120 mg, 180 mg and 240 mg strengths. The approved product is the generic version of Calan SR extended-release tablets, the company said in a statement.

 

Verapamil ER tablets are prescribed to lower high blood pressure, helping reduce the risk of serious cardiovascular events such as strokes and heart attacks.

Zydus signs exclusive licensing deal with RK Pharma 

The company has entered into an exclusive licensing and commercialisation agreement with US-based RK Pharma Inc. for a novel sterile injectable oncology supportive-care product intended for the US market.

 

Under the partnership, RK Pharma will manufacture and supply the finished product, while Zydus will handle the New Drug Application (NDA) submission and commercial launch in the United States.  ALSO READ | HDFC Securities starts coverage on Eureka Forbes with 'Buy'; check target 

The product has been developed under the 505(b)(2) regulatory pathway and is expected to be filed in 2026. Zydus said the formulation is designed to reduce dosing errors and improve compliance among healthcare professionals.

Zydus Q2 results 

Ahmedabad-headquartered company has posted a 17 per cent year-on-year (Y-o-Y) rise in revenue from operations to ₹6,123 crore, while net profit rose 38 per cent to ₹1,258.6 crore. Earnings before interest, tax, depreciation, and amortisation (Ebitda) for the quarter rose 38 per cent Y-o-Y to Rs 2,015.8 crore, with a resulting Ebitda margin of 32.9 per cent, an improvement of 500 basis points from a year earlier. Organic capex for the quarter stood at ₹491.1 crore.